US · Healthcare · Diagnostics & Research
EPS came in at 0.01 against a street estimate of -0.01 — a beat of 200.0%.
Analysts rate NeoGenomics Inc a buy (8 buy, 3 hold, 0 sell out of 11) with an average price target of $23.40.
CONFIDENT NeoGenomics delivered strong Q3 growth, led by NGS, expanding margins and raised 2026 revenue and EBITDA guidance. MRD adoption is emerging, while legacy pharma remains a drag. Q3 FY26 No geographic revenue breakdown was discussed. Analysts focused on leadership continuity, AUP durability, MRD commercialization, NGS share gains, payer coverage, margins and the declining pharma business. Management emphasized execution continuity, high-value mix, reimbursement progress and disciplined investment. 2026-10-28…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 16.24% |
| First Light Asset Management, LLC | 9.56% |
| First Trust Advisors L.P. | 7.87% |
| Greenhouse Funds LLLP | 6.67% |
| Vanguard Portfolio Management, LLC | 6.27% |
| Vanguard Capital Management, LLC | 4.49% |
| State Street Corp | 4.17% |
| Delaware Management Holdings Inc | 3.92% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $209,254, up from $187,797 in the third quarter of 2025. • Nine-month 2026 revenue was $597,582, u | 2026-10-28 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue increased 11% year over year to $209 million. • Clinical revenue rose 13% to $195 million, driven by 2 | 2026-10-28 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Preliminary third-quarter 2026 total revenue is expected to be approximately $209 million. • Next-generation sequencing (NGS) rev | 2026-10-05 |
| Board / officer change · Q3 2026 NEOGENOMICS, INC. - FORM 8-K SUMMARY OTHER NOTABLE POINTS • Executive Departure: Alicia Olivo, EVP of General Counsel & Business Development, is tra | 2026-08-11 |
| Quarterly report · Q2 2026 NEOGENOMICS, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $201.7 million (up 11% vs. Q2 2025: $181.3 million) • Six-Month 2026 Re | 2026-07-28 |
| Results announced · Q3 2026 NEOGENOMICS Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenue Q2 2026: $202 million, up 11% year-over-year from $181 million in Q2 2025 • Cl | 2026-07-28 |
| Reg FD disclosure · Q3 2026 NEOGENOMICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Settlement payment: $9,813,260 to U.S. Department of Justice • Prior reserve accrual (as of | 2026-07-20 |
| Board / officer change · Q2 2026 NEOGENOMICS, INC. — FORM 8-K SUMMARY OTHER NOTABLE POINTS • Board Expansion: Board of Directors increased from 9 to 10 members on June 23, 2026 • N | 2026-06-25 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for NeoGenomics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.